DOXOrubicin, liposomal
General
High Alert Medication: This medication bears a heightened risk of causing significant patient harm when it is used in error.
Pronunciation:
dox-oh-roo-bi-sin lye-poe-sohm-al
![](.//images/locked-audio.png)
Trade Name(s)
- Caelyx
- Doxil
Ther. Class.
Pharm. Class.
anthracyclines
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Vallerand, April Hazard., et al. "DOXOrubicin, Liposomal." Davis's Drug Guide, 18th ed., F.A. Davis Company, 2023. Nursing Central, nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/109376/all/DOXOrubicin_liposomal.
Vallerand AHA, Sanoski CAC, Quiring CC. DOXOrubicin, liposomal. Davis's Drug Guide. F.A. Davis Company; 2023. https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/109376/all/DOXOrubicin_liposomal. Accessed September 7, 2024.
Vallerand, A. H., Sanoski, C. A., & Quiring, C. (2023). DOXOrubicin, liposomal. In Davis's Drug Guide (18th ed.). F.A. Davis Company. https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/109376/all/DOXOrubicin_liposomal
Vallerand AHA, Sanoski CAC, Quiring CC. DOXOrubicin, Liposomal [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2023. [cited 2024 September 07]. Available from: https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/109376/all/DOXOrubicin_liposomal.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - DOXOrubicin, liposomal
ID - 109376
A1 - Sanoski,Cynthia A,
AU - Vallerand,April Hazard,
AU - Quiring,Courtney,
BT - Davis's Drug Guide
UR - https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/109376/all/DOXOrubicin_liposomal
PB - F.A. Davis Company
ET - 18
DB - Nursing Central
DP - Unbound Medicine
ER -